Chinese and Western Integrative Medicine for Stage IIIb-IVb Non-Small Cell Lung Cancer: Design and Rationale of a Multi-center, Prospective Registry (NSCLC-Chinese and Western Integrative Medicine cohort)

Integr Cancer Ther. 2023 Jan-Dec:22:15347354231185109. doi: 10.1177/15347354231185109.

Abstract

Introduction: This planned multicenter observational study will evaluate the overall survival of those undergoing integrated Chinese and Western medicine for stage IIIb-IVb non-small cell lung cancer and analyze the factors related to the prognosis.

Method and analysis: The prospective cohort will enroll patients with stage IIIb-IVb NSCLC from March 1, 2019, to December 31, 2025, and follow them for 5 years. We plan to collect data on the patients' demographics, treatment, overall survival, and factors related to the prognosis.

Ethics and dissemination: The institutional review board and ethics committee reviewed the study protocol. All patients will provide informed consent before enrollment.Trial registration number: ChiCTR1900021430.

Keywords: Chinese and Western integrative medicine; Registry study; non-small cell lung cancer.

Publication types

  • Observational Study
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoma, Non-Small-Cell Lung* / therapy
  • Humans
  • Integrative Medicine*
  • Lung Neoplasms* / therapy
  • Registries
  • Treatment Outcome

Associated data

  • ChiCTR/ChiCTR1900021430